How many times have you started to have a conversation with someone about Hepatitis C only to have it blow up in your face? Have you ever heard someone say something about Hep C that didn't seem quite right to you? You were probably right something was amiss. A discussion about Hepatitis C can...
As per Wikipedia, the definition of a stigma is as follows: "Stigma is a word that originally means a "sign", "point", or "branding mark"." Wikipedia goes on to call stigma "A badge of shame, a physical mark of infamy or disgrace." Damn that w...
Recently, the CDC (Center for Disease Control) issued a statement that all Baby Boomers should be tested for Hepatitis C. The question often comes up as to why this particular segment of people is so vulnerable. What does being born between 1945 and 1965 have to do with Hepatitis C? What was di...
Buyer Beware! There are several snake oil salesmen out there who are claiming to have cured their own Hepatitis C with herbs, supplements and parking lot gravel. Okay, maybe not the parking lot gravel but it might as well be. What you need to remember is that there are two different types of...
Most every adult woman (and an occasional man) has enjoyed a manicure and a pedicure at a nail salon or spa. That 30 minute pedicure can be so relaxing but are you aware of the danger lurking in that nail salon? Although few individuals recognize the medical risks associated with this common pr...
‘Psychosocial behavior’ a key to HIV treatment.
HIV/AIDS is no longer a death sentence. Just ask Dr. Eric Daar. “I’ve been treating HIV/AIDS patients since very early in the epidemic, when we spent most of our time just helping people die comfortably, until now, a period when we’re giving people hope. The majority of our patients hope for a long, healthy life,” said Daar.
Dr. Daar is chief of HIV Medicine at L.A. BioMed, practicing at Harbor-UCLA Medical Center in Torrance. This Palos Verdes resident, Southern California native and Georgetown University grad also works at Harbor as an investigator of medicine and teacher, and is a professor of medicine at Geffen School of Medicine at UCLA. “Too many titles,” he said with a laugh. Daar completed his residency and fellowship in infectious diseases at Cedar Sinai, served on the faculty and became chief of infectious diseases at Cedar. His tenure at Harbor “is about 10 years.” Los Angeles Biomedical Research Institute is acknowledged to be among the nation’s leading nonprofit facilities in health studies. In addition to research, L.A. BioMed trains young scientists and provides community services in most areas of health care.
Day by day
During a traditional work day, “I’m engaged in patient care. We have a clinic here at Harbor-UCLA campus where we take care of about a thousand people who have HIV, and then we have another clinic in a county-funded comprehensive care center in Long Beach, where we take care of about 250 patients. I’m involved in the direct care of these patients plus the teaching of our infectious disease fellows about HIV medicine” said Daar.
“In addition, in the afternoons I see patients admitted to the hospital who have HIV, most of the time, but occasionally with general infectious diseases where I depend on the consult service.” With the consult service, Daar said his staff sees every patient admitted to the hospital, regardless of what brought them to the facility. He teaches the fellows about managing HIV in-patients. “The nice thing is that when we have these patients in the hospital, we get to know them very well and, when they’re ready for discharge, they’ll often come back and see us in the clinic,” said Daar.
Harbor deals with what he calls a “challenged population. We take care of a lot of indigent, poor, immigrant patients, but we’re able to increase the likelihood that they will come back and improve with continuity of care. HIV care is really among today’s miracles of modern medicine in that we can take people who we meet in the emergency room who are diagnosed with advanced AIDS, get them through their complications and get them into clinic and then completely give them their lives back,” he said.
Initial involvement in HIV care
Part of Daar’s interest in HIV/AIDS stemmed from growing up when the disease first emerged. “I was in medical school when HIV/AIDS was first prescribed in Washington, D.C., when I was at Georgetown. Then it really began to explode in the years of my residency,” said Daar.
“During my training I started working in a research laboratory and became increasingly engaged in clinical research. It was interesting to be involved in something so new, at the very earliest stages, that was clearly to become something really big. And, I think I was attracted to it because it involved people who were my peers who were mostly my age. We were dealing with this life-changing diagnosis and early death.”
More research
Though the care and treatment of HIV is making great gains, Daar’s research continues.
“When I’m not dealing with patients,” said Daar, “we have a pretty large research program where we are doing everything from trying to understand why HIV causes disease, which includes everything from immune suppression – which is what most people think about – as well as a large program studying the affect HIV has on the brain, which we know is another major target for HIV infection.”
He also said there are current programs linking HIV and its treatment to other organs in the body, including the heart, liver, kidneys and bone. “We have studies on how to treat HIV itself; what are the best, safest and most tolerated of combinations, or cocktails, of drugs that can be used to help patients completely control the virus to live a normal, healthy life,” said Daar.
Please sign the ATC Salvage Therapy Petition Join us in asking Congressman Alcee Hastings and Congresswomen Maxine Waters to send a ‘Dear Colleague’ letter to Anthony Fauci, Director of NIAID, asking for the federal facilitation of apricitabine (ATC). ATC is a phase III nucleoside reverse transcriptase inhibitor (NRTI) that has been shown to be safe and effective in treating people with HIV. It works against viruses that are resistant to several other nukes and could ...
Researchers from Johns Hopkins Children’s Center, the University of Mississippi Medical Center and the University of Massachusetts Medical School announced today at CROI2013 the discovery of the first infant functionally cured of HIV. The baby, a female now two and a half years old, received 3 HIV medications when brought to the hospital at 30 hours old. Viral load tests were performed during the first few weeks that showed a rapidly decreasing viral load which reached ...
At the 19th International AIDS Conference (AIDS 2012) in Washington D.C., the CDC reported that only 1 out of 4 HIV patients in the U.S. have HIV under control, which is defined as complete viral suppression. Warning bells should be ringing in the scientific and HIV advocacy communities. While much progress has been made in the last three decades in the treatment of HIV, tens of thousands of people living with HIV (PLWH) are currently struggling to construct viable treat...
Paige Rawl is 17 and HIV positive, but while her life has been shaped by HIV it isn't ruled by it. When Paige Rawl starts her senior year at Indianapolis’s Herron High School next month, she'll be cheer captain and a member of the student government and prom committee. This summer, the 17-year-old held down a part-time job at Hollister, hawking the popular Southern California-inspired clothing brand. The all-American girl — who happens to be HIV positive. Paige was in...
The HIV community has been abuzz with the August FDA approval of what had been termed “the Quad”, the second one-pill-once-a-day combination antiretroviral drug. Marketed by Gilead under the name Stribild, the drug contains two NRTIs (tenofovir and emtricitabine), an integrase inhibitor (elvitegravir) and an integrase booster (cobicistat) and is approved for use in treatment naïve patients with either drug resistant or wild type virus. In comparison to Atripla, the first...

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for SUSTIVA® (efavirenz), including dosing recommendations for...

California and other states would be pressured to amend or repeal criminal laws that single out HIV-positive people under a bipartisan bill co-authored and introduced this week by Rep. Barbara...
Mission Statement
At HIV Haven we wish to provide our readers with vital cutting edge information to help expand HIV knowledge and promote activism, particularly that which works towards an end to the HIV pandemic. It is our desire to bring to you the scientific, medical and social advances that given the appropriate attention and support, could change the course of the HIV pandemic, lessen the devastating effects of HIV and AIDS, better the quality and quantity of life for people living with HIV and even yield an eventual end to the HIV pandemic. We also provide the basics of HIV transmission and treatment.
We will focus on issues such as innovative drug development, strategic activist campaigns, HIV relationships and novel HIV and HIV cure research. We also will bring you advances in Hepatitis C (HCV), a common HIV co-infection. Whether you are living with HIV/AIDS, HIV and HCV, love someone who is, are an activist, advocate, researcher, physician or just an interested party, we hope here at HIV Haven we can help you find what you are looking for.